Back to Search
Start Over
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder
- Source :
- British Journal of Psychiatry. 191:131-139
- Publication Year :
- 2007
- Publisher :
- Royal College of Psychiatrists, 2007.
-
Abstract
- BackgroundThe efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic.AimsTo compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder.MethodPatients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day).ResultsIn the 13-week phase, long-acting risperidone was at least as effective as (not inferior to) oral olanzapine. In the 12-month phase, significant improvements in the Positive and Negative Syndrome Scale (PANSS) total and factor scores from baseline to month 12 and end-point were seen in both groups of patients. Few patients discontinued treatment because of an adverse event.ConclusionsBoth treatments were efficacious and well tolerated.
- Subjects :
- Adult
Male
Olanzapine
medicine.medical_specialty
medicine.drug_class
Administration, Oral
Atypical antipsychotic
Schizoaffective disorder
Injections
law.invention
Benzodiazepines
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
030212 general & internal medicine
Risperidone
Positive and Negative Syndrome Scale
Dopamine antagonist
medicine.disease
030227 psychiatry
Psychiatry and Mental health
Treatment Outcome
Schizophrenia
Delayed-Action Preparations
Anesthesia
Patient Compliance
Female
Psychology
Antipsychotic Agents
Tablets
medicine.drug
Subjects
Details
- ISSN :
- 14721465 and 00071250
- Volume :
- 191
- Database :
- OpenAIRE
- Journal :
- British Journal of Psychiatry
- Accession number :
- edsair.doi.dedup.....986b1600cee3482f058d6e36f4be219a